WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases...
United States
Exonics Therapeutics, Inc., a newly formed biotechnology company
focused on developing gene editing technologies to permanently
correct a majority of mutations causing Duchenne muscular dystrophy
and other neuromuscular diseases, announced a commitment of $5
million in seed financing from CureDuchenne Ventures. The initial
seed funding will allow Exonics to advance the preclinical research
of its Scientific Founder and Chief Science Advisor Eric Olson,
PhD.
The WilmerHale team representing Exonics Therapeutics was led by
Gary Schall.
Read Exonics Therapeutics' press release for more information.
Contributor
WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
